Physician Assistant Program
Objective: In adults with major depressive disorder (MDD), does Esketamine treatment result in longer term results of reducing suicidal ideations when compared to transcranial magnetic stimulation (TMS) therapy over the course of their lifetime? Methods: Four studies were found using the Valparaiso University online library database to find peer-reviewed articles regarding treatment for pharmacoresistant MDD and reducing suicidal ideations within these individuals. Results: Esketamine therapy use in those with severe MDD has shown to produce stable remission among patients that completed a 16-week trial of the drug administration, with less than 30% falling into relapse. TMS therapy use in those with severe MDD with suicidal ideations have shown to provide lasting effects more than 12 months following administration, also with less than 30% relapse. Conclusion: While both treatment methods have shown to be effective, TMS therapy has shown to have longer lasting effects compared to Esketamine therapy before reintroduction of treatment is needed.
Keywords: major depressive disorder, pharmacoresistant therapy, suicidal ideations, Esketamine therapy, TMS therapy
Cameron, Samantha, "Duration of Effects from Esketamine vs TMS Therapy in Resolving Suicidal Ideations" (2023). Summer Interdisciplinary Research Symposium. 157.